NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Descending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72237-0101-06 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | June 22, 2020 | In Use | |
72237-0101-07 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | June 22, 2020 | In Use | |
55513-0730-01 | 55513-0730 | Denosumab | XGEVA | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Nov. 18, 2010 | In Use | |
00006-5331-01 | 00006-5331 | belzutifan | WELIREG | 40.0 mg/1 | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Oral | Aug. 13, 2021 | In Use | |
68727-0745-01 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
68727-0745-02 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
68727-0745-05 | 68727-0745 | (daunorubicin and cytarabine) liposome | Vyxeos | 100.0 mg/20mL, 44.0 mg/20mL | Chemotherapy | Antitumor Antibiotic & Antimetabolite | Anthracycline & Pyrimidine Analog | Intravenous | Aug. 3, 2017 | In Use | |
00078-0670-66 | 00078-0670 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | July 12, 2016 | Oct. 31, 2024 | In Use |
00173-0804-09 | 00173-0804 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | Oct. 19, 2009 | June 30, 2017 | No Longer Used |
00173-0804-61 | 00173-0804 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | Oct. 19, 2009 | Nov. 30, 2017 | No Longer Used |
50633-0210-11 | 50633-0210 | Glucarpidase | Voraxaze | 1000.0 [USP'U]/1 | Ancillary Therapy | Chemoprotective | Antidote | Intravenous | April 1, 2012 | In Use | |
72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb. 28, 2022 | In Use | |
63539-0197-90 | 63539-0197 | Dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb. 1, 2019 | In Use | |
00069-0197-30 | 00069-0197 | dacomitinib | Vizimpro | 15.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 4, 2018 | In Use | |
00069-2299-30 | 00069-2299 | dacomitinib | Vizimpro | 45.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 4, 2018 | In Use | |
00069-1198-30 | 00069-1198 | dacomitinib | Vizimpro | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Oct. 4, 2018 | In Use | |
69468-0151-04 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
69468-0151-10 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
69468-0151-20 | 69468-0151 | Uridine Triacetate | Vistogard | 951.0 mg/g | Ancillary Therapy | Chemoprotective | Antidote | Oral | March 1, 2016 | In Use | |
66758-0045-01 | 66758-0045 | Vinorelbine tartrate | Vinorelbine tartrate | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 13, 2008 | Oct. 6, 2014 | No Longer Used |
66758-0045-02 | 66758-0045 | Vinorelbine tartrate | Vinorelbine tartrate | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 13, 2008 | Oct. 6, 2014 | No Longer Used |
00008-0045-01 | 00008-0045 | Vinorelbine tartrate | Vinorelbine tartrate | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 13, 2008 | In Use | |
00008-0045-02 | 00008-0045 | Vinorelbine tartrate | Vinorelbine tartrate | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 13, 2008 | In Use | |
00703-4182-01 | 00703-4182 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2003 | Nov. 30, 2012 | No Longer Used |
00703-4182-91 | 00703-4182 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2003 | May 31, 2012 | No Longer Used |
00703-4183-01 | 00703-4183 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2003 | April 30, 2013 | No Longer Used |
00703-4183-91 | 00703-4183 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2003 | Dec. 31, 2012 | No Longer Used |
25021-0204-01 | 25021-0204 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 15, 2014 | In Use | |
25021-0204-05 | 25021-0204 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 15, 2014 | In Use | |
45963-0607-55 | 45963-0607 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2015 | In Use | |
45963-0607-56 | 45963-0607 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | March 1, 2015 | In Use | |
67457-0431-11 | 67457-0431 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
67457-0479-53 | 67457-0479 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
67457-0481-01 | 67457-0481 | Vinorelbine | Vinorelbine | 10.0 mg/mL, 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
67457-0482-05 | 67457-0482 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
50742-0420-01 | 50742-0420 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
50742-0427-05 | 50742-0427 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
61703-0341-06 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 9, 2007 | Oct. 31, 2017 | No Longer Used |
61703-0341-09 | 61703-0341 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | April 2, 2007 | May 31, 2019 | No Longer Used |
55390-0069-01 | 55390-0069 | Vinorelbine | Vinorelbine | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Feb. 11, 2004 | Dec. 31, 2012 | No Longer Used | ||
00069-0099-01 | 00069-0099 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
00069-0103-03 | 00069-0103 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
00069-0205-10 | 00069-0205 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
00069-0205-50 | 00069-0205 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sept. 1, 2012 | Aug. 31, 2016 | No Longer Used |
55390-0070-01 | 55390-0070 | Vinorelbine | Vinorelbine | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Feb. 11, 2004 | Dec. 31, 2012 | No Longer Used | ||
61703-0309-06 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Jan. 1, 1996 | In Use | |
61703-0309-16 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Jan. 1, 1996 | In Use | |
61703-0309-25 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Nov. 27, 2013 | In Use | |
61703-0309-26 | 61703-0309 | Vincristine Sulfate | Vincristine Sulfate | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Feb. 19, 2014 | In Use | |
00703-4402-11 | 00703-4402 | Vincristine Sulfate | Vincasar PFS | 1.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | May 1, 2000 | In Use |
Found 10,000 results in 2 milliseconds — Export these results